ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 317 filers reported holding ROYALTY PHARMA PLC in Q2 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,701 | -11.4% | 173,196 | +0.4% | 0.02% | -10.7% |
| Q2 2023 | $5,304 | -12.3% | 172,554 | +2.8% | 0.03% | -17.6% |
| Q1 2023 | $6,048 | -8.3% | 167,869 | +0.6% | 0.03% | -15.0% |
| Q4 2022 | $6,593 | -99.9% | 166,819 | +2.8% | 0.04% | -7.0% |
| Q3 2022 | $6,522,000 | -0.1% | 162,319 | +4.5% | 0.04% | +4.9% |
| Q2 2022 | $6,528,000 | +39.8% | 155,289 | +29.6% | 0.04% | +57.7% |
| Q1 2022 | $4,668,000 | -4.3% | 119,823 | -2.1% | 0.03% | 0.0% |
| Q4 2021 | $4,879,000 | +10.4% | 122,433 | +0.1% | 0.03% | 0.0% |
| Q3 2021 | $4,420,000 | -4.7% | 122,303 | +8.0% | 0.03% | -3.7% |
| Q2 2021 | $4,640,000 | -9.6% | 113,194 | -3.7% | 0.03% | -15.6% |
| Q1 2021 | $5,130,000 | +156.2% | 117,604 | +194.0% | 0.03% | +146.2% |
| Q4 2020 | $2,002,000 | +52.4% | 40,004 | +28.1% | 0.01% | +30.0% |
| Q3 2020 | $1,314,000 | – | 31,240 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |